Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165691 | 1.00 | NPSR1 (0.59) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL17398601 | 0.93 | NPSR1 (0.66) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL31375622 | 0.86 | KDM2B (0.69) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL16409435 | 0.86 | KDM2B (0.69) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL2080623 | 0.85 | KDM2B (0.68) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL953570 | 0.83 | NPSR1 (0.59) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| Hydrochloric Acid SCHEMBL15567275 | 0.82 | NPSR1 (0.58) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL4676459 | 0.82 | NPSR1 (0.58) | NPSR1MGLLKDM2BHSD11B1MEN1 | |
| SCHEMBL3515355 | 0.80 | NPC1 (0.52) | MGLLHSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL439217 | 0.80 | NPC1 (0.52) | MGLLHSD11B1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2615086-A1 | 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | NPSR1 4639/4885MGLL 4811/4885KDM2B 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.